You are here

Phase III Clinical Study of Lonafarnib in Non-Small-Cell Lung Cancer Discontinued

KENILWORTH, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Schering-Plough Research Institute (SPRI) today reported that it has voluntarily stopped enrollment in its Phase III clinical study of SARASAR™ (lonafarnib) in non-small-cell lung cancer (NSCLC). An analysis of interim data from this study led to the conclusion that the study will not provide sufficient evidence of efficacy to warrant further enrollment.

SPRI emphasized that it is continuing its Phase II clinical studies of SARASAR in leukemia and a variety of solid tumors. Schering-Plough noted that other companies' anticancer compounds (trastuzumab and gefitinib) also have failed to show efficacy in their recent studies in first-line NSCLC.

SARASAR is a member of a new class of compounds called FTI's that take a novel approach to treating cancer by inhibiting farnesyl transferase, a key enzyme involved in the regulation of the growth and proliferation of cancer cells. Inhibition of protein farnesylation alters the activity of a number of proteins important in tumor cell proliferation, including the Ras oncogene family.

Schering-Plough Research Institute is the pharmaceutical research and development arm of Schering-Plough Corporation , a research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products worldwide.

Source: Schering-Plough Research Institute

Recent Headlines

NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens
Primary Immunodeficiencies Affect 250,000 People in U.S.
More Than 25% of Patients Responded to Xpovio/Dexamethasone Combo
Attacks Cancerous Cells, Leaves Healthy Tissues Alone
Moderates Pre-diabetes Progression, Reduces Cholesterol Levels